Abstract 4660: Inhibition of p38 enhances ERK inhibitor efficacy in pancreatic ductal adenocarcinoma
Meagan B. Ryan(Sage Therapeutics (United States)), Channing J. Der(University of North Carolina at Chapel Hill), Kris C. Wood(Duke University), Tikvah K. Hayes(University of North Carolina at Chapel Hill), Swapnil S. Kher(University of North Carolina at Chapel Hill), Adrienne D. Cox(University of North Carolina at Chapel Hill), Kirsten L. Bryant(University of North Carolina at Chapel Hill), Ahmed A. Samatar(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 0
Related Papers
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Rho-family GTPases: it's not only Rac and Rho (and I like it)
|Journal of Cell Science|2004|594
Role of a Mitogen-activated Protein Kinase Pathway in the Induction of Phase II Detoxifying Enzymes by Chemicals
|Journal of Biological Chemistry|1999|280